To better your understanding of non-clinical career options and/or facilitate your physician career change, today we introduce you to Henry Hsu, M.D., Chief Medical Officer, of CoMentis, a pharmaceutical company engaged in the discovery and development of small-molecule drugs to treat Alzheimer’s disease, age-related macular degeneration (AMD) and cognitive disorders.
Dr. Hsu joined CoMentis in September 2005 as Chief Medical Officer. Prior to joining CoMentis, he was Vice President for Clinical Research at CoTherix, Inc., where he was responsible for the clinical submission of a New Drug Application for Ventavis (inhaled iloprost), which received priority review and was approved by the FDA in 2004. From 2000 to 2004, he was employed at InterMune, Inc, as Vice President, Clinical Research, responsible for leading clinical research and development in the liver and infectious diseases therapeutic areas. From 1995 to 2000, he was Medical Director, Clinical Research, at Chiron Corporation, where he conducted clinical research in the areas of vaccines and cytokines.
Dr. Hsu holds an M.D. degree from the University of California, San Francisco, and completed Internal Medicine training at the University of California, Davis, where he served a Chief Medical Resident. He obtained subspecialty training in gastroenterology and hepatology at Stanford University as well as completing a research fellowship in molecular virology as a Howard Hughes Medical Institute Research Fellow. Dr. Hsu received his Bachelor of Arts degree from The Johns Hopkins University.
For more information about Dr. Hsu and CoMentis, please visit the company website.
